Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aim: To determine whether earlier administration of insulin glargine (glargine) vs. the intensification of lifestyle management (LM) improves glycaemic control in type 2 diabetes patients with A1c 7–8% treated with oral therapy. Methods: TULIP [Testing the Usefulness of gLargine when Initiated Promptly in type 2 diabetes mellitus (T2DM)] was a 9‐month, 12‐visit, open‐label, multinational, multicentre, randomized study to evaluate starting glargine or intensifying LM in T2DM patients aged 40–75 years, body mass index (BMI) 24–35 kg/m 2 and A1c 7–8%, treated with maximum doses of metformin and sulphonylurea for ≥ 2 years. Glargine was injected once daily (evening) and titrated to fasting blood glucose 0.7–1.0 g/l. In the LM arm, dietary and physical activity counselling recommended stable weight for people with BMI < 27 kg/m 2 or weight loss of 3 kg for patients with BMI ≥ 27 kg/m 2 . A total of 215 patients were randomized to glargine (n = 106) or LM (n = 109). The primary objective was patients achieving A1c < 7% at endpoint. Secondary endpoints included changes in A1c, in fasting plasma glucose (FPG), body weight and hypoglycaemia incidence. Results: Two hundred and eleven (52.6% male) patients were randomized and treated; mean (± s.d.) age 60.7 ± 7.9 years, weight 84.5 ± 13.1 kg, BMI 29.9 ± 3.5 kg/m 2 and A1c 7.6 ± 0.4%. More patients reached A1c < 7% (66 vs. 38%; p < 0.0001) or < 6.5% (34 vs. 11%; p = 0.0001) with glargine vs. LM. The change in FPG from baseline to study endpoint was significantly greater in the glargine vs. the LM arm (−0.50 ± 0.47 vs. −0.05 ± 0.39 g/l respectively; p < 0.0001). Compared with the glargine group, the LM group showed a decrease in weight (+0.9 ± 2.9 vs. −2.5 ± 3.2 kg; p < 0.0001), as well as the expected lower symptomatic hypoglycaemia (55.3 vs. 25.0%; p < 0.0001) and nocturnal hypoglycaemia (20.4 vs. 5.6%; p = 0.0016). No significant changes were observed from baseline to study endpoint in any of the lipid parameters tested. Conclusions: In patients with T2DM with A1c 7–8%, who were previously treated by conventional LM and OAD therapy, adding glargine resulted in greater improvements in glycaemic control vs. intensifying LM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Cited by
Blonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Effect of gender on treatment outcomes in type 2 diabetes mellitus
McGill, J. B., Vlajnic, A., Knutsen, P. G., Recklein, C., Rimler, M., & Fisher, S. J. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.10.001 · Cited by 61
“This pooled analysis included patient-level data from nine similarly designed phase 3 or 4, randomized, controlled, prospective clinical trials evaluating the effect of insulin glargine versus an active comparator treatment (neutral protamine Hagedorn [NPH] insulin, insulin lispro, premixed insulin, oral antidiabetes…”
BackgroundMethodInfluentialGarg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Metadata
- Authors
- Blicklé, J., Hancu, N., Piletic, M., Profozic, V., Shestakova, M., Dain, M., Jacqueminet, S., & Grimaldi, A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2009-02-24
- Volume
- 11
- Issue
- 4
- Pages
- 379-386
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2050249722
- Cited by
- 52
- References
- 3
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00980.x
- The paper
- Blicklé, J., Hancu, N., Piletic, M., Profozic, V., Shestakova, M., Dain, M., Jacqueminet, S., & Grimaldi, A. (2009). Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00980.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.